Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Patent Expiration Does Not Signal a Savings Date, Cautions SHARx's Paul Pruitt


      News provided by

      SHARx

      Nov 16, 2026, 08:09 ET

      Share this article

      Share this article


      Patent expiration doesn't necessarily mean savings are right around the corner. SHARx's Paul Pruitt says employers need a pharmacy strategy for the costs they face today and the potential for high-price options to emerge before the generics hit the shelves. 

      ST. LOUIS, Nov. 16, 2026 /PRNewswire/ -- A drug nearing patent expiration may seem like relief from high prices, but lower-cost competition can still take years to reach the market.

      Employers cannot control when a patent expires, a lawsuit is resolved, or when a biosimilar reaches the market. They can, however, evaluate how their pharmacy benefits are structured and what options are available to manage prescription costs today.

      Continue Reading
      "In simple terms, no one should build a pharmacy budget assuming that patent expiration automatically means lower costs next year or even the year after. We know what the results are only when competition does enter the market. The longer meaningful competition is delayed, the longer employers and patients are left managing the higher cost of the existing therapy.” - Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx
      "In simple terms, no one should build a pharmacy budget assuming that patent expiration automatically means lower costs next year or even the year after. We know what the results are only when competition does enter the market. The longer meaningful competition is delayed, the longer employers and patients are left managing the higher cost of the existing therapy.” - Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx

      "Adalimumab shows how long U.S. employers can wait for lower-cost competition; approximately six and a half years passed between approval of the first biosimilar and its U.S. launch. In other markets, the wait was about two years, so we know the timeline could be shorter," Pruitt noted.

      Setting New Timetables

      "What's more is that, in the U.S., drugmakers have other ways to keep generics out of patients' hands." Pruitt explains how, even after a patent's time is up, drugmakers may make minimal adjustments to the same drug or launch a new drug that treats the same condition(s) as the old drug. These moves reset the patent clock on the new, high-priced version of the medication while heavily marketing the new version to doctors and patients."

      Patent Expiration Does Not Signal a Savings Date

      These delays are fueled by several factors. Manufacturers can use multiple strategies to protect market share after the initial patent, including overlapping patents, modified versions of existing products, and the launch of replacement medications. These gaps can leave employers knowing that a major biologic is approaching the end of patent protection without knowing when a competing product will reach the market or at what price.  

      "What does that delay mean? In simple terms, no one should build a pharmacy budget assuming that patent expiration automatically means lower costs next year or even the year after. We know what the results are only when competition does enter the market," Pruitt said. "The longer meaningful competition is delayed, the longer employers and patients are left managing the higher cost of the existing therapy."

      Employers Still Have Decisions to Make

      Pruitt encourages employers to examine how the pharmacy benefit manager (PBM) defines value and how formulary decisions align with the plan's lowest net cost. He also recommends looking beyond typical discounts and rebates to understand the actual net cost of medications and whether their members can be directed towards clinically appropriate, lower-cost options.

      "It starts with asking, 'Are the PBM's incentives and formulary decisions actually aligned with the employer's lowest net cost?'" Pruitt said. "Plan design is another area to review when several effective treatments are available. For conditions which have multiple effective treatments, ask whether there is a plan to encourage the higher-value options." Pruitt said. "There may be medications that are equally effective for some patients but much less expensive."

      Competition Has to Produce Measurable Savings

      Biosimilar competition is another factor that can produce significant savings when it reaches the market. Kaiser Permanente reported that biosimilars typically cost about 30% less than their brand-name biologic counterparts and reduced U.S. drug spending by an estimated $20 billion in 2024.

      Pruitt said policymakers should protect incentives for pharmaceutical innovation while ensuring competition can reach employers and patients within a reasonable time frame.

      "Patents are designed to give manufacturers a reward for innovation, but drug patents have not been that straightforward," Pruitt said. "Once competition exists, market forces work great. The problem comes when competition is not allowed to function."

      About SHARx

      SHARx is a procurement and supply chain management solution for high-cost prescription drugs. Working alongside employer-sponsored health plans, SHARx helps employers address the financial impact of expensive and specialty medications while providing members with personalized advocacy and access to cost-effective sourcing solutions. Learn more at SHARXplan.com 

      References

      • Amgen. (2023, January 31). AMJEVITA™ (adalimumab-atto), first biosimilar to HUMIRA®, now available in the United States.
      • Bettelheim, A. (2026, September 15). Biosimilars stuck in a rut. Axios.
      • Hayes, M. (2026, September 25). Want to lower drug prices? Reform the U.S. patent system. Kaiser Permanente.
      • Purvis, L., Kaltenboeck, A., & Chen, J. (2026, September 22). No easy solutions: Brand name drug companies have many ways to slow generic competition. AARP Public Policy Institute.

      Media inquiries:
      Karla Jo Helms
      JOTO PR™
      727-777-4629
      Jotopr.com

      SOURCE SHARx

      Modal title

      Also from this source

      SHARx is Raising Up an Influential Rx Army

      SHARx is Raising Up an Influential Rx Army

      Sophie Cunningham stands with SHARx. (Watch Sophie Cunningham's Fair Play.) She is part of a team of respected athletes committed to lowering drug...

      The Pharmacy Budget Trap: SHARx Warns Discounts Alone Cannot Control Total Spending

      The Pharmacy Budget Trap: SHARx Warns Discounts Alone Cannot Control Total Spending

      A larger rebate does not guarantee lower pharmacy spending, warns Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx, a procurement management ...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Supply Chain/Logistics

      Supply Chain/Logistics

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Computer & Electronics

      Computer & Electronics

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.